Haitham M Ahmed1, Stanley L Hazen2,3. 1. Preventive Cardiology and Rehabilitation, Cleveland Clinic, Heart and Vascular Institute, 9500 Euclid Ave, Desk JB1, Cleveland, OH, 44195, USA. ahmedh3@ccf.org. 2. Preventive Cardiology and Rehabilitation, Cleveland Clinic, Heart and Vascular Institute, 9500 Euclid Ave, Desk JB1, Cleveland, OH, 44195, USA. 3. Department of Cellular and Molecular Medicine, Cleveland Clinic, Lerner Research Institute, Cleveland, OH, USA.
Abstract
PURPOSE OF REVIEW: Since identification of aspartate aminotransferase as the first cardiac biomarker in the 1950s, there have been a number of new markers used for myocardial damage detection over the decades. There have also been several generations of troponin assays, each with progressively increasing sensitivity for troponin detection. Accordingly, the "standard of care" for myocardial damage detection continues to change. The purpose of this paper is to review the clinical utility, biological mechanisms, and predictive value of these various biomarkers in contemporary clinical studies. RECENT FINDINGS: As of this writing, a fifth "next" generation troponin assay has now been cleared by the US Food and Drug Administration for clinical use in the USA for subjects presenting with suspected acute coronary syndromes. Use of these high-sensitivity assays has allowed for earlier detection of myocardial damage as well as greater negative predictive value for infarction after only one or two serial measurements. Recent algorithms utilizing these assays have allowed for more rapid rule-out of myocardial infarction in emergency department settings. In this review, we discuss novel assays available for the risk assessment of subjects presenting with chest pain, including both the "next generation" cardiac troponin assays as well as other novel biomarkers. We review the biological mechanisms for these markers, and explore the positive and negative predictive value of the assays in clinical studies, where reported. We also discuss the potential use of these new markers within the context of future clinical care in the modern era of higher sensitivity troponin testing. Finally, we discuss advances in new platforms (e.g., mass spectrometry) that historically have not been considered for rapid in vitro diagnostic capabilities, but that are taking a larger role in clinical diagnostics, and whose prognostic value and power promise to usher in new markers with potential for future clinical utility in acute coronary syndrome.
PURPOSE OF REVIEW: Since identification of aspartate aminotransferase as the first cardiac biomarker in the 1950s, there have been a number of new markers used for myocardial damage detection over the decades. There have also been several generations of troponin assays, each with progressively increasing sensitivity for troponin detection. Accordingly, the "standard of care" for myocardial damage detection continues to change. The purpose of this paper is to review the clinical utility, biological mechanisms, and predictive value of these various biomarkers in contemporary clinical studies. RECENT FINDINGS: As of this writing, a fifth "next" generation troponin assay has now been cleared by the US Food and Drug Administration for clinical use in the USA for subjects presenting with suspected acute coronary syndromes. Use of these high-sensitivity assays has allowed for earlier detection of myocardial damage as well as greater negative predictive value for infarction after only one or two serial measurements. Recent algorithms utilizing these assays have allowed for more rapid rule-out of myocardial infarction in emergency department settings. In this review, we discuss novel assays available for the risk assessment of subjects presenting with chest pain, including both the "next generation" cardiac troponin assays as well as other novel biomarkers. We review the biological mechanisms for these markers, and explore the positive and negative predictive value of the assays in clinical studies, where reported. We also discuss the potential use of these new markers within the context of future clinical care in the modern era of higher sensitivity troponin testing. Finally, we discuss advances in new platforms (e.g., mass spectrometry) that historically have not been considered for rapid in vitro diagnostic capabilities, but that are taking a larger role in clinical diagnostics, and whose prognostic value and power promise to usher in new markers with potential for future clinical utility in acute coronary syndrome.
Authors: Till Keller; Stergios Tzikas; Tanja Zeller; Ewa Czyz; Lars Lillpopp; Francisco M Ojeda; Alexander Roth; Christoph Bickel; Stephan Baldus; Christoph R Sinning; Philipp S Wild; Edith Lubos; Dirk Peetz; Jan Kunde; Oliver Hartmann; Andreas Bergmann; Felix Post; Karl J Lackner; Sabine Genth-Zotz; Viviane Nicaud; Laurence Tiret; Thomas F Münzel; Stefan Blankenberg Journal: J Am Coll Cardiol Date: 2010-05-11 Impact factor: 24.094
Authors: J B Lawrence; C Oxvig; M T Overgaard; L Sottrup-Jensen; G J Gleich; L G Hays; J R Yates; C A Conover Journal: Proc Natl Acad Sci U S A Date: 1999-03-16 Impact factor: 11.205
Authors: C M Phelan; C Larsson; S Baird; P A Futreal; M H Ruttledge; K Morgan; P Tonin; H Hung; R G Korneluk; M N Pollak; S A Narod Journal: Genomics Date: 1996-05-15 Impact factor: 5.736
Authors: Michael J Lipinski; Nevin C Baker; Ricardo O Escárcega; Rebecca Torguson; Fang Chen; Sally J Aldous; Michael Christ; Paul O Collinson; Steve W Goodacre; Johannes Mair; Kenji Inoue; Ulrich Lotze; Mustapha Sebbane; Jean-Paul Cristol; Yonathan Freund; Camille Chenevier-Gobeaux; Christophe Meune; Kai M Eggers; Radosław Pracoń; Donald H Schreiber; Alan H B Wu; Jordi Ordoñez-Llanos; Allan S Jaffe; Raphael Twerenbold; Christian Mueller; Ron Waksman Journal: Am Heart J Date: 2014-10-22 Impact factor: 4.749
Authors: Aernout Luttun; Marc Tjwa; Lieve Moons; Yan Wu; Anne Angelillo-Scherrer; Fang Liao; Janice A Nagy; Andrea Hooper; Josef Priller; Bert De Klerck; Veerle Compernolle; Evis Daci; Peter Bohlen; Mieke Dewerchin; Jean-Marc Herbert; Roy Fava; Patrick Matthys; Geert Carmeliet; Désiré Collen; Harold F Dvorak; Daniel J Hicklin; Peter Carmeliet Journal: Nat Med Date: 2002-07-01 Impact factor: 53.440
Authors: Zeneng Wang; W H Wilson Tang; Leslie Cho; Danielle M Brennan; Stanley L Hazen Journal: Arterioscler Thromb Vasc Biol Date: 2009-06-18 Impact factor: 8.311